Q4 2024 EPS Estimates for IDEXX Laboratories, Inc. (NASDAQ:IDXX) Cut by Analyst

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Stock analysts at William Blair cut their Q4 2024 earnings per share (EPS) estimates for shares of IDEXX Laboratories in a report released on Wednesday, May 1st. William Blair analyst R. Daniels now expects that the company will post earnings per share of $2.62 for the quarter, down from their prior forecast of $2.70. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.13 per share. William Blair also issued estimates for IDEXX Laboratories’ Q1 2025 earnings at $3.08 EPS, Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.16 EPS, Q4 2025 earnings at $3.17 EPS and FY2025 earnings at $12.63 EPS.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group upped their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. Finally, Barclays upped their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Stock Down 5.0 %

Shares of IDXX stock opened at $468.04 on Thursday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. IDEXX Laboratories has a twelve month low of $372.50 and a twelve month high of $583.39. The stock has a 50 day moving average of $527.12 and a 200 day moving average of $512.32. The stock has a market cap of $38.87 billion, a P/E ratio of 46.48, a P/E/G ratio of 3.85 and a beta of 1.27.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same period in the prior year, the company earned $2.05 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis.

Insider Buying and Selling at IDEXX Laboratories

In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last quarter. 2.11% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. OFI Invest Asset Management purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $25,000. Valley National Advisers Inc. boosted its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $28,000. Finally, Covestor Ltd raised its position in shares of IDEXX Laboratories by 71.8% during the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after buying an additional 28 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.